MX2020000295A - Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. - Google Patents
Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.Info
- Publication number
- MX2020000295A MX2020000295A MX2020000295A MX2020000295A MX2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted benzoxazole
- pde7 inhibitors
- benzofuran compounds
- chemical entities
- benzofuran
- Prior art date
Links
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 title abstract 2
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 title 1
- 150000001907 coumarones Chemical class 0.000 title 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 1
- -1 benzofuran chemical entities Chemical class 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531802P | 2017-07-12 | 2017-07-12 | |
| PCT/US2018/041565 WO2019014305A1 (en) | 2017-07-12 | 2018-07-11 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000295A true MX2020000295A (es) | 2020-07-22 |
Family
ID=63036485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000295A MX2020000295A (es) | 2017-07-12 | 2018-07-11 | Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11685745B2 (https=) |
| EP (1) | EP3652180B1 (https=) |
| JP (1) | JP7213863B2 (https=) |
| KR (1) | KR102640696B1 (https=) |
| CN (1) | CN111094293B (https=) |
| AU (1) | AU2018300091B2 (https=) |
| CA (1) | CA3069432A1 (https=) |
| MX (1) | MX2020000295A (https=) |
| WO (1) | WO2019014305A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11685745B2 (en) | 2017-07-12 | 2023-06-27 | Dart Neuroscience, Llc | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors |
| JP2022541954A (ja) * | 2019-07-17 | 2022-09-28 | 小野薬品工業株式会社 | Ｋｄｍ５阻害活性を有する化合物およびその医薬用途 |
| CN112574202B (zh) * | 2020-12-11 | 2021-11-09 | 台州学院 | 一种螺喹唑啉-2-酮类衍生物及其制备方法和应用 |
| IL318817A (en) | 2022-08-18 | 2025-04-01 | Mitodicure Gmbh | Use of a therapeutic agent with PHOSPHODIESTERASE-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exercise intolerance |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US7491742B2 (en) | 1999-10-21 | 2009-02-17 | Merck Patent Gmbh | Imidazole derivatives as phosphodiesterase VII inhibitors |
| DE19953024A1 (de) | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
| DE19953025A1 (de) | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
| DE19953414A1 (de) | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
| DE19954707A1 (de) | 1999-11-13 | 2001-05-17 | Merck Patent Gmbh | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
| WO2001083772A1 (en) | 2000-04-28 | 2001-11-08 | Merck Patent Gmbh | Splice variant of camp phosphodiesterase type 7 (pde7a3) |
| GB0015095D0 (en) | 2000-06-20 | 2000-08-09 | Celltech Chiroscience Ltd | Chemical compounds |
| KR100821410B1 (ko) | 2000-07-11 | 2008-04-10 | 에이엠알 테크놀로지, 인크. | 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도 |
| ATE526020T1 (de) | 2000-08-10 | 2011-10-15 | Cold Spring Harbor Lab | Gesteigertes kognitives training |
| US9931318B2 (en) | 2003-04-08 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| WO2002076953A1 (en) * | 2001-03-21 | 2002-10-03 | Warner-Lambert Company Llc | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| US6815448B2 (en) | 2001-05-07 | 2004-11-09 | Wyeth | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| MX2007000214A (es) | 2004-07-01 | 2007-05-10 | Asubio Pharma Co Ltd | Derivado de tienopirazol que tiene actividad inhibidora de pde 7. |
| EP1855686A1 (en) | 2005-03-01 | 2007-11-21 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
| BRPI0619126A2 (pt) | 2005-12-02 | 2011-09-13 | Pfizer Ltd | derivados espirocìclicos, composição farmacêutica e usos dos mesmos |
| JP2010527243A (ja) | 2007-05-15 | 2010-08-12 | ヘリコン セラピューティクス，インコーポレイテッド | 低分子干渉ＲＮＡ（ｓｉＲＮＡ）を用いた記憶形成に関わる遺伝子の同定方法 |
| CA2687944A1 (en) | 2007-05-24 | 2008-11-27 | Pfizer Limited | Spirocyclic quinazoline derivatives and their use as pde7 inhibitors |
| US11685745B2 (en) | 2017-07-12 | 2023-06-27 | Dart Neuroscience, Llc | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors |
-
2018
- 2018-07-11 US US16/629,922 patent/US11685745B2/en active Active
- 2018-07-11 CN CN201880058047.XA patent/CN111094293B/zh active Active
- 2018-07-11 KR KR1020207003770A patent/KR102640696B1/ko active Active
- 2018-07-11 JP JP2020501229A patent/JP7213863B2/ja active Active
- 2018-07-11 CA CA3069432A patent/CA3069432A1/en active Pending
- 2018-07-11 EP EP18746513.3A patent/EP3652180B1/en active Active
- 2018-07-11 WO PCT/US2018/041565 patent/WO2019014305A1/en not_active Ceased
- 2018-07-11 AU AU2018300091A patent/AU2018300091B2/en active Active
- 2018-07-11 MX MX2020000295A patent/MX2020000295A/es unknown
-
2023
- 2023-06-15 US US18/210,382 patent/US12319702B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12319702B2 (en) | 2025-06-03 |
| CA3069432A1 (en) | 2019-01-17 |
| CN111094293B (zh) | 2025-08-01 |
| JP7213863B2 (ja) | 2023-01-27 |
| EP3652180B1 (en) | 2023-11-29 |
| KR102640696B1 (ko) | 2024-02-27 |
| AU2018300091A1 (en) | 2020-01-30 |
| CN111094293A (zh) | 2020-05-01 |
| EP3652180A1 (en) | 2020-05-20 |
| US20240199643A1 (en) | 2024-06-20 |
| US20220267351A1 (en) | 2022-08-25 |
| WO2019014305A1 (en) | 2019-01-17 |
| JP2020526546A (ja) | 2020-08-31 |
| AU2018300091B2 (en) | 2023-06-22 |
| US11685745B2 (en) | 2023-06-27 |
| KR20200027994A (ko) | 2020-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| WO2015048547A3 (en) | Methods for using and biomarkers for ampk-activating compounds | |
| MX2020000295A (es) | Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. | |
| NZ711598A (en) | Substituted naphthyridine and quinoline compounds as mao inhibitors | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| UA113156C2 (xx) | Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak | |
| CR20210530A (es) | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona | |
| PH12014502396B1 (en) | Nitrogenated heterocyclic compound | |
| MX2015016085A (es) | Derivados de heterociclicos. | |
| EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| EA201201677A1 (ru) | Производные гетероарилимидазолона в качестве ингибиторов jak | |
| MX381230B (es) | Novedoso compuesto de 1,2,4-triazina disustituida. | |
| EA201691461A1 (ru) | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения | |
| BR112015022474A2 (pt) | compostos substituídos de piridina e pirazina como inibidores de pde4 | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| MX2020006290A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
| EA201490438A1 (ru) | Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные циклопента[c]пирролом | |
| MX380677B (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| EA201591698A1 (ru) | Макроциклические ингибиторы киназы lrrk2 | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| EA201790207A1 (ru) | Новые замещенные пиримидиновые соединения | |
| MX2015015162A (es) | Agente de reduccion de acido urico. | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect |